Cargando…

Correction: The effects of myeloablative or non-myeloablative total body irradiations on intestinal tract in mice

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2022
Materias:	Corrections
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301291/ https://www.ncbi.nlm.nih.gov/pubmed/35856572 http://dx.doi.org/10.1042/BSR-2020-2993_COR

Ejemplares similares

The effects of myeloablative or non-myeloablative total body irradiations on intestinal tract in mice
por: Zhu, Shengyun, et al.
Publicado: (2021)

Correction: Splenocytes Seed Bone Marrow of Myeloablated Mice: Implication for Atherosclerosis
Publicado: (2015)

Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity
por: Stephens, Sarah J., et al.
Publicado: (2016)

Factors associated with pulmonary toxicity after myeloablative conditioning using fractionated total body irradiation
por: Byun, Hwa Kyung, et al.
Publicado: (2017)

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
por: Atilla, Erden, et al.
Publicado: (2017)

Phase I trial of myeloablative conditioning with 3‐day total marrow and lymphoid irradiation for leukemia
por: Ogawa, Hiroaki, et al.
Publicado: (2022)

Reduced-toxicity myeloablative conditioning consisting of 8-Gy total body irradiation, cyclophosphamide and fludarabine for pediatric hematological malignancies
por: Hirabayashi, Koichi, et al.
Publicado: (2014)

High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation
por: Nakamura, R, et al.
Publicado: (2002)

Comparison of Non-myeloablative Conditioning Regimens for Lymphoproliferative Disorders
por: Hong, Sanghee, et al.
Publicado: (2014)

Correction: Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study
por: Willasch, Andre Manfred, et al.
Publicado: (2021)

Splenocytes Seed Bone Marrow of Myeloablated Mice: Implication for Atherosclerosis
por: Wang, Lai, et al.
Publicado: (2015)

Targeting Myeloid Cells to the Brain Using Non-Myeloablative Conditioning
por: Böttcher, Chotima, et al.
Publicado: (2013)

Correction of T-Cell Repertoire and Autoimmune Diabetes in NOD Mice by Non-myeloablative T-Cell Depleted Allogeneic HSCT
por: Sidlik Muskatel, Rakefet, et al.
Publicado: (2023)

Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-Cell Interaction
por: van Balen, Peter, et al.
Publicado: (2018)

Effect on lifespan of high yield non-myeloablating transplantation of bone marrow from young to old mice
por: Kovina, Marina V., et al.
Publicado: (2013)

National survey of myeloablative total body irradiation prior to hematopoietic stem cell transplantation in Japan: survey of the Japanese Radiation Oncology Study Group (JROSG)
por: Ishibashi, Naoya, et al.
Publicado: (2018)

Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma
por: Campbell, P, et al.
Publicado: (2014)

Myeloablative treatment supported by autologous stem cell infusion with neuroblastoma.
por: Ryu, Kyung Ha, et al.
Publicado: (2003)

Comparison of gamma and x-ray irradiation for myeloablation and establishment of normal and autoimmune syngeneic bone marrow chimeras
por: Wittenborn, Thomas Rea, et al.
Publicado: (2021)

Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem cell transplantation (SCT) in patients with refractory hematologic malignancies
por: Bhatnagar, Bhavana, et al.
Publicado: (2013)

P1273: COMPARISON OF TOTAL BODY IRRADIATION-BASED WITH CHEMOTHERAPY-BASED MYELOABLATIVE CONDITIONING REGIMENS IN PATIENTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION
por: Mengnan, LV, et al.
Publicado: (2023)

Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
por: Nissani, Abraham, et al.
Publicado: (2021)

Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation
por: Treister, Nathaniel, et al.
Publicado: (2017)

Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning
por: Wagner, John E., et al.
Publicado: (2021)

P1315: THE CHRONOLOGICAL SEQUENCE OF 12 GY TOTAL BODY IRRADIATION AND CYCLOPHOSPHAMIDE CONDITIONING DOES NOT IMPACT OUTCOMES IN AML PATIENTS UNDERGOING MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
por: Franke, Georg-Nikolaus, et al.
Publicado: (2023)

Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study
por: Sun, Zimin, et al.
Publicado: (2018)

Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies
por: Li, Qingshan, et al.
Publicado: (2015)

Pilot experience with opebacan/rBPI (21) in myeloablative hematopoietic cell transplantation
por: Guinan, Eva, et al.
Publicado: (2015)

Fibrinolysis-independent role of plasmin and its activators in the haematopoietic recovery after myeloablation
por: Tjwa, Marc, et al.
Publicado: (2009)

Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas
por: Zhenyang, Gu, et al.
Publicado: (2021)

Thrombopoietin from hepatocytes promotes hematopoietic stem cell regeneration after myeloablation
por: Gao, Longfei, et al.
Publicado: (2021)

Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?
por: Cameron, D A, et al.
Publicado: (2002)

Primary Graft Failure after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
por: Olsson, Richard F., et al.
Publicado: (2015)

Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning
por: Bremer, Sara, et al.
Publicado: (2015)

Myeloablative Chemotherapy with Autologous Stem Cell Transplant for Desmoplastic Small Round Cell Tumor
por: Forlenza, Christopher J., et al.
Publicado: (2015)

Myeloablation-associated deletion of ORF4 in a human coronavirus 229E infection
por: Greninger, Alexander L., et al.
Publicado: (2017)

Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation
por: Ayoglu, Burcu, et al.
Publicado: (2023)

Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities
por: Popat, Uday R., et al.
Publicado: (2023)

Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias
por: Fierro-Pineda, Juan C., et al.
Publicado: (2023)

Myeloablative Temozolomide Enhances CD8(+) T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice
por: Sanchez-Perez, Luis A., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ph2sd3h8k4cg1kvmars1b6nlnd